Hundreds of clinical trials and digital studies are conducted each year by Sutter Health to better understand, detect, treat ...

Neuralink is crossing the pond. Elon Musk’s brain chip is due to start clinical trials in Great Britain, and he is inviting ...

Clinical trial patient recruitment and retention practices have significantly advanced over the last 15 years thanks to ...

These 10 stocks could mint the next wave of millionaires › Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its ...

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...

Neuralink launched the first European clinical trial in the UK to test brain implants that let paralyzed patients control ...

The FDA has approved VIZZ, a once-daily, preservative-free eye drop that improves near vision in adults with presbyopia for up to 10 hours.

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.

Annette Benton fought for years to have the truth come out about her pregnancy and child. One year after her death, it's ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell’s proprietary IDDC™ platform. Its highly optimized structure integrates three key elements: Mab0727: A highly specific CDH17 ...